Key Developments: Abbott Laboratories (ABT)

ABT on New York Consolidated

48.76USD
27 May 2015
Change (% chg)

$0.16 (+0.33%)
Prev Close
$48.60
Open
$48.87
Day's High
$48.92
Day's Low
$48.59
Volume
237,866
Avg. Vol
4,724,556
52-wk High
$49.43
52-wk Low
$39.28

Search Stocks

Latest Key Developments (Source: Significant Developments)

Abbott Laboratories to purchase Topera Inc
Wednesday, 29 Oct 2014 09:30am EDT 

Abbott Laboratories:Entered into an agreement to purchase Topera, Inc., a private, venture-backed medical device company focused on developing electrophysiology technologies to improve the diagnosis and treatment of atrial fibrillation.Completion of the Topera acquisition is subject to customary closing conditions, including antitrust clearance.Expected to close in the fourth quarter of this year.  Full Article

Abbott Laboratories narrows FY 2014 EPS outlook to a range above analysts' estimates; gives Q4 2014 EPS outlook in line with analysts' estimates
Wednesday, 22 Oct 2014 07:32am EDT 

Abbott Laboratories:Says it is raising the mid-point and narrowing its FY 2014 earnings-per-share guidance, excluding specified items, to $2.25 to $2.27 from $2.19 to $2.29, representing double-digit growth.Says including net specified items, projected earnings per share under GAAP would be $1.22 to $1.24 for FY 2014, including results from both continuing and discontinued operations.Expects Q4 2014 earnings-per-share guidance, excluding specified items, of $0.68 to $0.70, representing double-digit growth.Expects Q4 2014 including specified items, projected earnings-per-share under GAAP would be $0.32 to $0.34.FY 2014 EPS of $2.24 - Thomson Reuters I/B/E/S.Q4 2014 EPS of $0.70 - Thomson Reuters I/B/E/S.  Full Article

Abbott completes acquisition of CFR Pharmaceuticals
Friday, 26 Sep 2014 09:00am EDT 

Abbott Laboratories:Says has acquired control of CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence and further expanding company's presence in fast-growing markets.Through purchase of controlling interest and tender offers described below, Abbott indirectly acquired more than 99 pct of CFR's ordinary shares for about $2.9 bln.  Full Article

Abbott Laboratories II study shows abbott's dissolving heart device comparable to Heart stent
Sunday, 14 Sep 2014 03:00pm EDT 

Abbott Laboratories:Announces positive one year clinical results from ABSORB II, the prospective, randomized, controlled trial comparing the safety and effectiveness of the dissolving Absorb heart device to Abbott's metallic XIENCE family of DES.Says the trial, conducted primarily in Europe, included 501 people with coronary artery disease (CAD), the most common form of heart disease.  Full Article

Abbott Laboratories announces new $3 bln share repurchase program, declares dividend
Thursday, 11 Sep 2014 01:39pm EDT 

Abbott Laboratories:Authorizes the repurchase of up to $3 billion of the corporation's common shares.Purchases may be made from time to time as market conditions warrant and subject to regulatory considerations.Declares quarterly common dividend of $0.22 per share.Cash dividend is payable Nov. 15, to shareholders of record at the close of business on Oct. 15.  Full Article

Abbott receives CE mark for FreeStyle Libre
Wednesday, 3 Sep 2014 09:30am EDT 

Abbott Laboratories:Receives CE Mark (Conformite Europeenne) for its FreeStyle Libre Flash Glucose Monitoring System, a new glucose sensing technology for people with diabetes.The system eliminates the need for routine finger pricks1, reading glucose levels through a sensor that can be worn on the back of the upper arm for up to 14 days.  Full Article

Abbott Laboratories commences tender offer for all outstanding ordinary shares and american depositary shares of CFR Pharmaceuticals S.A
Monday, 25 Aug 2014 09:00am EDT 

Abbott Laboratories:Announced that Abbott Laboratories (Chile) Holdco (Dos) SpA, a Chilean corporation (ALH) subsidiary has commenced tender offer (U.S. Offer).Says offer in which it is offering to purchase from U.S. holders only, up to 100 pct of outstanding ordinary, nominative, no par value shares of CFR Pharmaceuticals S.A. (CFR) Chilean corporation and from all holders, wherever resident, up to 100 pct of outstanding American Depositary Shares.Tender Offer for shares and ADS issued dated as of May 9, 2011, between CFR and The Bank of New York Mellon, as Depositary.Says each of which represents 100 ordinary shares, in each case, on terms and subject to conditions set forth in U.S. Offer to Purchase, dated Aug. 25, 2014, and in related ordinary share acceptance letter and ADS Letter of Transmittal, as applicable.Says U.S. Offer will expire on Sept. 23 unless U.S. Offer is extended.  Full Article

Abbott Laboratories declares 362nd quarterly dividend
Wednesday, 16 Jul 2014 07:45am EDT 

Abbott Laboratories:Declares quarterly dividend of $0.22 per share.Payable on Aug. 15 to shareholders of record at the close of business on July 15.  Full Article

Abbott Laboratories raises FY 2014 EPS outlook
Wednesday, 16 Jul 2014 07:45am EDT 

Abbott Laboratories:Raised FY 2014 ongoing earnings-per-share guidance range to $2.19 to $2.29 from $2.16 to $2.26.Expects FY 2014 GAAP EPS in the range of $1.16 to $1.26.Says guidance for both ongoing and GAAP EPS from continuing operations includes the developed markets branded generics pharmaceuticals business, which is expected to be reported as discontinued operations starting in the Q3 2014.FY 2014 EPS of $2.19 - Thomson Reuters I/B/E/S.  Full Article

Mylan Inc to acquire Abbott Laboratories's non-U.S. developed markets specialty and branded generics business
Monday, 14 Jul 2014 06:30am EDT 

Mylan Inc:Has entered into a definitive agreement with Abbott Laboratories whereby Mylan will acquire Abbott's non-U.S. developed markets specialty and branded generics business in an all-stock transaction.Upon closing, Abbott will receive 105 million shares of the combined company worth about $5.3 billion based on Mylan's closing price of $50.20 on July 11, representing an about 21 pct ownership stake.  Full Article

PRESS DIGEST- New York Times business news - May 26

May 26 - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy.

Search Stocks